RxDoctor Payments Data

Karol Sanchez

Hospitalist · Titusville, FLNPI 1609281559

Payments from drug & device makers

$652in general payments, 2019–2025

Across 23 payments — averaging $28.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$406
  • Johnson & Johnson$74
  • Kestra Medical Technology Services, Inc.$65
  • Pfizer Pharmaceuticals LLC$39
  • Pfizer$23
  • PBG Puerto Rico LLC$18
  • plus $28 from 2 others

What the payments were for

  • Food & beverage$652100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boehringer Ingelheim10$406
Johnson & Johnson4$74
Kestra Medical Technology Services, Inc.3$65
Pfizer Pharmaceuticals LLC2$39
Pfizer1$23
PBG Puerto Rico LLC1$18
Mallinckrodt Hospital Products Inc.1$15
E.r. Squibb & Sons, L.L.C.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$652 in reported general payments places this provider in the 75th percentile of 1,570 hospitalist providers in Florida.

See all hospitalist providers in Florida

Medicare billing

Part B allowed, 2024
$91,058
Medicare patients
290
Services billed
949

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban17$8,528
Albuterol Sulfate HfaAlbuterol Sulfate12$308
Pantoprazole Sodium41$228
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav28$176
Doxycycline Hyclate30$152
Amiodarone Hcl16$149
Ciprofloxacin Hcl14$87
Metoprolol Tartrate20$81
Methylprednisolone11$55
Atorvastatin Calcium11$52
Furosemide20$50
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen13$49
Prednisone12$33
Amlodipine Besylate19$31
Losartan Potassium12$24

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$23$8,52817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,570 hospitalist providers in Florida.

Other hospitalist in Titusville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →